Abstract:Abstract Myeloid derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs) are two of the more immunosuppressive cell types in a tumor microenvironment (TME). Although TAMs and MDSCs can be converted from tumor-supporting to tumor-suppressing phenotypes by treatment with proinflammatory immune stimulants (e.g. TLR7 agonists) in vitro, such strategies have proven to be too toxic in vivo because of their systemic activation of immune cells. Therefore, for such immune stimulants to be used to reprogram the immune system in solid tumors, they must be targeted specifically to the immune cells in the TME. One strategy for targeting TAMs/MDSCs is to exploit a receptor that is expressed solely on these cell types. Because folate receptor beta (FRβ) is expressed exclusively on myeloid cells and since FRβ acquires its ability to bind folic acid (FA) only in inflamed tissues, we have previously exploited FA to target attached TLR7 agonists (TLR7a) to FRβ+ TAMs/MDSCs in solid tumors. While significant repolarization of TAMs and MDSCs was observed in this previous study, premature systemic release of the attached TLR7a caused unwanted toxicity. However, since FRβ was later found to reside in the same endosome as TLR7, we hypothesized that constructing a more stable FA-TLR7a conjugate with a non-cleavable linker should not only prevent premature TLR7a release, but also deposit the FA-TLR7a into an endosome containing a TLR7 receptor, thereby enabling selective activation of TAMs and MDSCs in the TME. The data summarized here confirm this hypothesis. Thus, free TLR7-1A was found to stimulate massive production of IL-6, TNF-α and IFNγ upon addition to human peripheral blood in vitro or injected into live mice, suggesting cells in both species respond aggressively to TLR7-1A. However, performance of the same studies with FA-targeted TLR7-1A stimulated barely or nondetectable levels of the inflammatory cytokines, confirming that FA-TLR7-1A is unable to enter and activate cells that lack a folate receptor (FRβ). More importantly, intravenous administration of FA-TLR7-1A into mice bearing an orthotopic 4T1 breast tumor totally blocked metastases and induced tumor regression without causing detectable toxicity. Flow cytometric analyses of the residual tumor tissue further demonstrated that FA-TLR7-1A increased M1/M2 macrophage ratios and elevated infiltration of CD8+ T cells into the tumor masses. Taken together, these data demonstrate that a targeted TLR7 agonist can rejuvenate immune cells in a solid tumor without systemically activating the immune system. Citation Format: John Victor Napoleon, Fenghua Zhang, Rami A. Alfar, Taylor A. Wolt, Philip S. Low. Reprogramming of tumor-infiltrating immune cells using a tumor-associated macrophage-targeted TLR7 agonist [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB028.

Lactoferrin-containing Immunocomplex Mediates Antitumor Effects by Resetting Tumor-Associated Macrophages to M1 Phenotype.

In situ repolarization of Tumor-Associated Macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy

570 Blockade of the Inhibitory Collagen Receptor LAIR-1, PD-L1, and TGF-β Promotes Anti-Tumor Activity Through T Cell Activation and Myeloid Cell Polarization

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Tumor Microenvironment Remodeling And Tumor Therapy Based On M2-Like Tumor Associated Macrophage-Targeting Nano-Complexes

Antibody-Decorated Nanoplatform to Reprogram Macrophage and Block Immune Checkpoint LSECtin for Effective Cancer Immunotherapy

Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages

d -lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma

M860, a Monoclonal Antibody Against Human Lactoferrin, Enhances Tumoricidal Activity of Low Dosage Lactoferrin Via Granzyme B Induction

Ferumoxytol-Beta-Glucan Inhibits Melanoma Growth Via Interacting With Dectin-1 To Polarize Macrophages Into M1 Phenotype

FoxO1 is a Regulator of MHC-II Expression and Anti-Tumor Effect of Tumor-Associated Macrophages

Abstract 2671: Sustained inhibition of CSF1R signaling effectively augments antitumor immune responses through inhibiting tumor-associated macrophages

LAMTOR1 Phosphorylation of Exo70 Facilitates Tumor-Associated Macrophage Polarization to Restrain CD8+ T Cell Function in HCC

M2-TAM Subsets Altered by Lactic Acid Promote T-cell Apoptosis Through the PD-L1/PD-1 Pathway

Harnessing Tumor-Associated Macrophages As Aids for Cancer Immunotherapy

Concomitant Type I IFN and M-CSF Signaling Reprograms Monocyte Differentiation and Drives Pro-Tumoral Arginase Production

Anti-tumor Macrophages Activated by Ferumoxytol Combined or Surface-Functionalized with the TLR3 Agonist Poly (I : C) Promote Melanoma Regression.

In Situ Reprogramming of Tumor-Associated Macrophages Enhances Cancer Immunotherapy

Abstract LB028: Reprogramming of tumor-infiltrating immune cells using a tumor-associated macrophage-targeted TLR7 agonist

Combination of Cryo‐Shocked M1 Macrophages and Lonidamine Nanodrugs Enables Potent Chemo‐Immunotherapy

Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function